Sílvia Gómez-Zorrilla

ORCID: 0000-0002-5987-068X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Antibiotic Resistance in Bacteria
  • Antibiotics Pharmacokinetics and Efficacy
  • Antibiotic Use and Resistance
  • COVID-19 Clinical Research Studies
  • Urinary Tract Infections Management
  • Bacterial biofilms and quorum sensing
  • Pneumonia and Respiratory Infections
  • SARS-CoV-2 and COVID-19 Research
  • Long-Term Effects of COVID-19
  • Bacterial Identification and Susceptibility Testing
  • Antimicrobial Resistance in Staphylococcus
  • Sepsis Diagnosis and Treatment
  • Nosocomial Infections in ICU
  • Streptococcal Infections and Treatments
  • Drug-Induced Adverse Reactions
  • Pharmaceutical and Antibiotic Environmental Impacts
  • COVID-19 and healthcare impacts
  • Pharmaceutical studies and practices
  • COVID-19 diagnosis using AI
  • Machine Learning in Healthcare
  • Fungal Infections and Studies
  • Trace Elements in Health
  • Dermatology and Skin Diseases
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Vibrio bacteria research studies

Hospital Del Mar
2021-2025

Universitat Autònoma de Barcelona
2020-2025

Universitat Pompeu Fabra
2019-2025

Centro de Investigación Biomédica en Red
2022-2025

Instituto de Salud Carlos III
2020-2025

Hospital del Mar Research Institute
2019-2023

Red Espanola de Investigacion en Patologia Infecciosa
2019-2022

Centre for Biomedical Network Research on Rare Diseases
2022

Parc de Salut
2021

Municipal Institute for Medical Research
2021

Belén Gutiérrez‐Gutiérrez Elena Salamanca Marina de Cueto Po‐Ren Hsueh Pierluigi Viale and 84 more José Ramón Paño‐Pardo Mario Venditti Mario Tumbarello George L. Daikos Rafael Cantón Yohei Doi Felipe Francisco Tuon Ilias Karaiskos Elena Pérez‐Nadales Mitchell J. Schwaber Özlem Kurt Azap Maria Souli Emmanuel Roilides Spyros Pournaras Murat Akova Federico Pérez Joaquín Bermejo Antonio Oliver Manel Almela Warren Lowman Benito Almirante Robert A. Bonomo Yehuda Carmeli David L. Paterson Álvaro Pascual Jesús Rodríguez‐Baño María Dolores del Toro Juan Gálvez-Acebal Marco Falcone Alessandro Russo Helen Giamarellou Enrico Maria Trecarichi Angela Raffaella Losito Elisa García‐Vázquez Alicia Hernández Juana Carretero Gómez Germán Bou Εlias Iosifidis Núria Prim Ferrán Navarro Beatriz Mirelis Anna Skiada Julia Origüen Rafael San Juan Mario Fernández‐Ruiz Nieves Larrosa Mireia Puig‐Asensio José Miguel Cisneros José Molina V. González V. Rucci E. Ruiz de Gopegui C. Marinescu Luis Martínez‐Martínez M.C. Fariñas M.E. Cano Mónica Gozalo Marta Mora-Rillo Carolina Navarro-San Francisco Carmen Peña Sílvia Gómez-Zorrilla Fé Tubau Athanassios Tsakris Olympia Zarkotou Anastasia Antoniadou Garyphallia Poulakou Johann Pitout Divya Virmani Julián Torre-Cisneros Julia Guzmán-Puche Özant Helvacı Ahmet Şahin Vicente Pintado Pablo Ramos-Ruiz Michele Bartoletti Maddalena Giannella E. Tacconelli F Riemenschneider Esther Calbo Cristina Badía Mariona Xercavins Oriol Gasch D. Fontanals E. Jové

10.1016/s1473-3099(17)30228-1 article EN The Lancet Infectious Diseases 2017-04-22

Using a large multicenter prospective cohort of Pseudomonas aeruginosa bacteremia, we demonstrate that the exoU type III secretion system genotype is independently associated with increased risk early mortality bloodstream infections, whereas late multidrug-resistant profiles. Background. The (TTSS) major virulence determinant aeruginosa. objective this study was to determine whether TTSS useful prognostic marker P. bacteremia mortality. We also studied potential association between...

10.1093/cid/ciu866 article EN Clinical Infectious Diseases 2014-11-06

This study assessed the molecular epidemiology, resistance mechanisms, and susceptibility profiles of a collection 150 extensively drug-resistant (XDR) Pseudomonas aeruginosa clinical isolates obtained from 2015 Spanish multicenter study, with particular focus on resistome analysis in relation to ceftolozane-tazobactam susceptibility. Broth microdilution MICs revealed that nearly all (>95%) were nonsusceptible piperacillin-tazobactam, ceftazidime, cefepime, aztreonam, imipenem, meropenem,...

10.1128/aac.01589-17 article EN Antimicrobial Agents and Chemotherapy 2017-09-05

10.1016/j.mayocp.2016.06.024 article EN Mayo Clinic Proceedings 2016-10-01

Zinc is an essential micronutrient that impacts host-pathogen interplay at infection. balances immune responses, and also has a proven direct antiviral action against some viruses. Importantly, zinc deficiency (ZD) common condition in elderly individuals with chronic diseases, two groups increased risk for severe coronavirus disease 2019 (COVID-19) outcomes. We hypothesize serum content (SZC) influences COVID-19 progression, thus might represent useful biomarker.

10.3390/nu13020562 article EN Nutrients 2021-02-09

Abstract Objectives To investigate pharmacokinetics (PK) and safety (primary objectives) efficacy (secondary objective) of the investigational monobactam/β-lactamase inhibitor combination aztreonam/avibactam in patients with complicated intra-abdominal infection (cIAI). Methods This Phase 2a open-label, multicentre study (NCT02655419; EudraCT 2015-002726-39) enrolled adults cIAI into sequential cohorts for 5–14 days treatment. Cohort 1 received an loading dose 500/137 mg (30 min infusion),...

10.1093/jac/dkz497 article EN cc-by-nc Journal of Antimicrobial Chemotherapy 2019-12-06

Background: The first wave of COVID-19 pandemic may have significantly impacted antimicrobial consumption in hospitals. objective this study was to assess the evolution during period. Methods: A retrospective quasi-experimental before–after conducted a Spanish tertiary care hospital. compared two periods: pre-pandemic, from January 2018 February 2020, and March June 2020. Antimicrobial analyzed monthly as defined daily doses (DDD)/100 bed-days overall hospital ICU were evaluated. Results: An...

10.3390/antibiotics10020132 article EN cc-by Antibiotics 2021-01-29

ABSTRACT The potential role of Pseudomonas aeruginosa (PA) intestinal colonization in the subsequent development infections has not been thoroughly investigated. aims this study were to assess PA as a predictor and investigate risk factors associated with infection patients intensive care unit (ICU). For purpose, prospective was conducted that included (i) active surveillance rectal at ICU admission weekly until discharge, (ii) detection clinical infections, (iii) genotypic analysis by...

10.1128/aac.04636-14 article EN Antimicrobial Agents and Chemotherapy 2015-06-16

ABSTRACT The intestinal reservoir is central to the epidemiology of Pseudomonas aeruginosa , but dynamics colonization by different phenotypes have been poorly described. To determine impact antimicrobial exposure on multidrug-resistant (MDR) and extensively drug-resistant (XDR) P. we screened intensive care unit (ICU) patients for rectal admission at weekly intervals. During an 18-month study period, 414 ICU were enrolled, whom 179 (43%) colonized; 112 (63%) these identified 67 (37%) during...

10.1128/aac.03419-14 article EN Antimicrobial Agents and Chemotherapy 2014-07-22

There is little information about the efficacy of active alternative drugs to carbapenems except β-lactam/β-lactamase inhibitors for treatment bloodstream infections (BSIs) due extended-spectrum β-lactamase–producing Enterobacteriaceae (ESBL-E). The objective this study was assess outcomes patients with BSI ESBL-E who received empiric therapy such (other [OADs]) or carbapenems. A multinational retrospective cohort OADs performed. Cox regression including a propensity score receiving...

10.1093/cid/cix606 article EN Clinical Infectious Diseases 2017-07-13

Abstract Background Acute skin and soft tissue infections (ASSTIs) represent a common reason for attending emergency department (ED) hospitalization. We investigate characteristics of cohort ASSTIs-patients comparing patients managed with hospitalization versus outpatients. Methods Retrospective study all consecutive adults who consulted to an ED due ASSTIs. Setting: Hospital del Mar (Barcelona, Spain). Period: January 2018–December 2020. Sample size (320) was calculated detect 10%...

10.1093/bjs/znaf024.005 article EN British journal of surgery 2025-02-01

Abstract Background/Objectives To assess the microbiological and clinical features of Klebsiella pneumoniae healthcare-associated bacteraemia urinary origin (HCA-BUO) in Spain, with a particular focus on third generation cephalosporin-(3GCR-Kp) carbapenem-resistant (CR-Kp) isolates. Methods A total 96 (21.4%, 96/449) K. blood isolates were prospectively collected from patients HCA-BUO (n=443) 12 tertiary-care hospitals Spain (2017-2019). Antimicrobial susceptibility was determined (standard...

10.1093/ofid/ofaf164 article EN cc-by-nc-nd Open Forum Infectious Diseases 2025-03-15

OBJECTIVE: To describe a case of levetiracetam-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. CASE SUMMARY: A 31-year-old white male low-grade astrocytoma presenting tonic-clonic seizures was treated levetiracetam 1 g twice daily dexamethasone (initial dosage 12 mg/day, tapered down to 2 mg/day). On day 45 after initiation, discontinued continued. The patient developed fever dyspnea on 46 admitted the hospital 49. chest X-ray showed bilateral pulmonary...

10.1345/aph.1r084 article EN Annals of Pharmacotherapy 2012-07-01

CD4/CD8 ratio has been used as a quantitative prognostic risk factor in patients with viral infections. This study aims to assess the association between in-hospital mortality and at admission among individuals acute SARS-CoV-2 infection.This is longitudinal cohort data of all consecutive admitted COVID-19 unit Hospital del Mar, Barcelona, Spain for ≥48 h March May 2020. The CD4+ CD8+ T-cell subset differentiation was assessed by flow cytometry well complete blood test. Patients were...

10.3389/fmed.2022.924267 article EN cc-by Frontiers in Medicine 2022-06-23

Treatment failure occurs in about 25% of patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. We assessed whether cloxacillin plus fosfomycin achieves better treatment success than alone hospitalized adults MSSA conducted a multicenter, open-label, phase III-IV superiority randomized clinical trial. randomly assigned (1:1) to receive 2 g intravenous every 4 h or 3 6 for the initial 7 days. The primary endpoint was at day 7, composite following criteria: patient...

10.1038/s41591-023-02569-0 article EN cc-by Nature Medicine 2023-10-01

To compare results of amoxicillin/clavulanate susceptibility testing using CLSI and EUCAST methodologies to evaluate their impact on outcome in patients with bacteraemia caused by Enterobacteriaceae.A prospective observational cohort study was conducted 13 Spanish hospitals. Patients due Enterobacteriaceae who received empirical intravenous treatment for at least 48 h were included. MICs determined following recommendations. Outcome variables were: failure the end (FEAMC); day 21; 30...

10.1093/jac/dkw562 article EN Journal of Antimicrobial Chemotherapy 2016-12-08

More data are needed about the safety of antibiotic de-escalation in specific clinical situations as a strategy to reduce exposure broad-spectrum antibiotics. The aims this study were investigate predictors and its impact on outcome patients with bloodstream infection due Enterobacteriaceae (BSI-E).A post hoc analysis was performed prospective, multicenter cohort BSI-E initially treated ertapenem or antipseudomonal β-lactams. Logistic regression used analyze factors associated early (EDE)...

10.1093/cid/ciy1032 article EN Clinical Infectious Diseases 2018-12-04

Abstract Objectives To assess the microbiological characteristics of Escherichia coli causing healthcare-associated bacteraemia urinary origin (HCA-BUO) in Spain (ITUBRAS-2 project), with particular focus on ESBL producers and isolates belonging to ST131 high-risk clone (HiRC). Clinical outcomes associated infection were investigated. Methods A total 222 E. blood prospectively collected from patients HCA-BUO 12 tertiary-care hospitals (2017–19). Antimicrobial susceptibility...

10.1093/jac/dkad234 article EN Journal of Antimicrobial Chemotherapy 2023-08-03
Coming Soon ...